Sumanth Kidambi1, Burhan Mohamedali2, Geetha Bhat1. 1. Division of Advanced Heart Failure and Clinical Transplantation, Advocate Christ Medical Center, Oak Lawn, IL, USA. 2. Rush University, Chicago, IL, USA.
Abstract
BACKGROUND: Left ventricular assist devices (LVADs) as a bridge to transplant (BTT) have been known to cause allosensitization, as measured by panel-reactive antibody (PRA) levels. The goal of this study was to measure the impact of this allosensitization on outcomes. METHODS: Panel-reactive antibodies were analyzed in BTT patients, with sensitization defined as peak PRAs ≥ 10%. Baseline characteristics and outcomes in the two patient groups were evaluated using descriptive statistics, Kaplan-Meier, and regression analysis. RESULTS: Thirty-eight patients were included in the study (17 sensitized vs. 21 non-sensitized). There were more women in the sensitized group (47% vs. 10%, p = 0.023). There was no difference in mean times to high-grade acute cellular rejection (ACR; 18.3 months in sensitized vs. 36.9 months in non-sensitized). Five patients in the sensitized groups developed antibody-mediated rejection (AMR) vs. 0 in the non-sensitized, and all five patients died (Kaplan-Meier log-rank p = 0.024). There was also a significant difference in the incidence of infection at the one- to six-month stage (52.9% vs. 19.0%, p = 0.03). CONCLUSION: Sensitization appears to have a negative effect on mortality. This mortality appears to be concentrated in patients with AMR, and we postulate that the development of AMR in a sensitized patient may be a predictor of mortality.
BACKGROUND: Left ventricular assist devices (LVADs) as a bridge to transplant (BTT) have been known to cause allosensitization, as measured by panel-reactive antibody (PRA) levels. The goal of this study was to measure the impact of this allosensitization on outcomes. METHODS: Panel-reactive antibodies were analyzed in BTTpatients, with sensitization defined as peak PRAs ≥ 10%. Baseline characteristics and outcomes in the two patient groups were evaluated using descriptive statistics, Kaplan-Meier, and regression analysis. RESULTS: Thirty-eight patients were included in the study (17 sensitized vs. 21 non-sensitized). There were more women in the sensitized group (47% vs. 10%, p = 0.023). There was no difference in mean times to high-grade acute cellular rejection (ACR; 18.3 months in sensitized vs. 36.9 months in non-sensitized). Five patients in the sensitized groups developed antibody-mediated rejection (AMR) vs. 0 in the non-sensitized, and all five patients died (Kaplan-Meier log-rank p = 0.024). There was also a significant difference in the incidence of infection at the one- to six-month stage (52.9% vs. 19.0%, p = 0.03). CONCLUSION: Sensitization appears to have a negative effect on mortality. This mortality appears to be concentrated in patients with AMR, and we postulate that the development of AMR in a sensitized patient may be a predictor of mortality.
Authors: David K C Cooper; Martin Wijkstrom; Sundaram Hariharan; Joshua L Chan; Avneesh Singh; Keith Horvath; Muhammad Mohiuddin; Arielle Cimeno; Rolf N Barth; John C LaMattina; Richard N Pierson Journal: Transplantation Date: 2017-07 Impact factor: 4.939
Authors: Sarah B See; Kevin J Clerkin; Peter J Kennel; Feifan Zhang; Matthew P Weber; Kortney J Rogers; Debanjana Chatterjee; Elena R Vasilescu; George Vlad; Yoshifumi Naka; Susan W Restaino; Maryjane A Farr; Veli K Topkara; Paolo C Colombo; Donna M Mancini; P Christian Schulze; Bruce Levin; Emmanuel Zorn Journal: J Heart Lung Transplant Date: 2017-03-24 Impact factor: 10.247
Authors: Lauren V Huckaby; Laura M Seese; Edgar Aranda-Michel; Michael A Mathier; Gavin Hickey; Mary E Keebler; Ibrahim Sultan; Thomas G Gleason; Arman Kilic Journal: Ann Thorac Surg Date: 2020-05-04 Impact factor: 4.330
Authors: Richard N Pierson; Lars Burdorf; Joren C Madsen; Gregory D Lewis; David A D'Alessandro Journal: Am J Transplant Date: 2020-05-25 Impact factor: 9.369